Valuation: Natera, Inc.

Market Cap 38.64B 33.78B 31.24B 28.67B 54.25B 3,724B 55.19B 373B 146B 1,818B 145B 142B 6,278B P/E 2026 *
-162x
P/E 2027 * -1,168x
Enterprise Value 37.6B 32.86B 30.39B 27.89B 52.78B 3,623B 53.7B 362B 142B 1,769B 141B 138B 6,108B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 11.2x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day-1.61%
1 week-2.03%
Current month-2.57%
1 month+16.80%
3 months+26.91%
6 months+12.62%
Current year+15.45%
1 week 261.63
Extreme 261.63
282
1 month 219.5
Extreme 219.5
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
7/13/26 Sell

Founder

-3,150 0.0022%
7/6/26 Sell

Founder

-1,000 0.0007%
7/1/26 Sell

General Counsel

-16,800 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%-2.03%+84.46%+437.02% 38.64B
+1.09%+3.05%+15.37%+34.17% 23.12B
+0.64%+2.43%-19.79%-38.73% 7.52B
-2.27%-5.46%+5.40%+90.77% 4.95B
-2.61%+0.17%+13.04%+43.21% 3B
-1.33%-7.74%-24.70%+712.89% 1.83B
-5.48%+15.20%-9.38%-65.57% 1.91B
-2.53%+2.09%+114.36%-16.20% 1.93B
-13.79%-0.44%+20.21%-27.31% 1.91B
+8.70%+1.77%+30.75%+8.30% 1.75B
Average -1.89%-1.62%+22.97%+117.85% 8.66B
Weighted average by Cap. -0.89%-1.79%+43.74%+220.36%

Financials

2026 *2027 *
Net sales 2.8B 2.44B 2.26B 2.07B 3.93B 270B 3.99B 26.96B 10.59B 132B 10.5B 10.27B 454B 3.33B 2.91B 2.69B 2.47B 4.67B 321B 4.75B 32.09B 12.6B 157B 12.5B 12.22B 541B
Net income -225M -196M -182M -167M -316M -21.66B -321M -2.17B -851M -10.58B -844M -826M -36.52B -28.71M -25.09M -23.21M -21.29M -40.3M -2.77B -41M -277M -109M -1.35B -108M -105M -4.66B
Net Debt -1.05B -917M -848M -778M -1.47B -101B -1.5B -10.11B -3.97B -49.34B -3.94B -3.85B -170B -1.32B -1.15B -1.07B -979M -1.85B -127B -1.89B -12.72B -5B -62.1B -4.96B -4.85B -214B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-17 US$264.33 -2.04% 291,933
26-07-16 US$269.83 -2.72% 948,974
26-07-15 US$277.37 +1.73% 867,755
26-07-14 US$272.66 -0.08% 954,842
26-07-13 US$272.89 +1.09% 1,528,001
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
269.83USD
Average target price
282.14USD
Spread / Average Target
+4.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock